Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade.
Antibodies that attenuate immune tolerance have been used to effectively treat cancer, but they can also trigger severe autoimmunity. To investigate this, we combined anti-CTLA-4 treatment with a standard colitis model to give mice a more severe form of the disease. Pretreatment with an antibiotic, vancomycin, provoked an even more severe, largely fatal form, suggesting that a Gram-positive component of the microbiota had a mitigating effect. We then found that a commonly used probiotic, Bifidobacterium, could largely rescue the mice from immunopathology without an apparent effect on antitumor immunity, and this effect may be dependent on regulatory T cells.
['Wang|Feng|F|', 'Yin|Qian|Q|', 'Chen|Liang|L|', 'Davis|Mark M|MM|']
D000818:Animals D057134:Antibodies, Neutralizing D001644:Bifidobacterium D060908:CTLA-4 Antigen D003092:Colitis D051379:Mice D008822:Mice, Transgenic D014640:Vancomycin
Bifidobacterium intestinal immunopathology CTLA-4 probiotics immune checkpoint blockade